Xeris Biopharma Holdings, Inc.
XERS
$5.99
-$0.09-1.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 124.23% | 316.72% | 103.95% | 87.15% | 51.42% |
| Total Depreciation and Amortization | 2.13% | 2.04% | 2.08% | 0.32% | -2.21% |
| Total Amortization of Deferred Charges | 5.33% | 5.10% | 4.98% | 1.61% | 47.29% |
| Total Other Non-Cash Items | -6.82% | 46.24% | 169.88% | 22.65% | 749.52% |
| Change in Net Operating Assets | 93.47% | 21.31% | 810.39% | -103.19% | -64.05% |
| Cash from Operations | 198.39% | 914.84% | 321.94% | 101.76% | 50.59% |
| Capital Expenditure | -2,400.00% | -51.36% | 18.39% | 29.72% | 92.07% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,400.00% | -103.32% | -100.72% | -106.06% | 99.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 68.28% | 125.89% | -- | 153.80% | 959.04% |
| Repurchase of Common Stock | -112.77% | -827.71% | -475.90% | -1,586.27% | -132.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -181.70% | -166.83% | 16,786.75% | 42.94% | -108.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 105.37% | 56.95% | 2,010.81% | 116.61% | -176.97% |